Egetis (Q3 review): Focus on US application - Redeye
Bildkälla: Stockfoto

Egetis (Q3 review): Focus on US application - Redeye

Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and the recent ReTRIACt readout.

Börsvärldens nyhetsbrev